A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
Cancers (Basel)
; 14(12)2022 Jun 20.
Article
en En
| MEDLINE
| ID: mdl-35740697
Texto completo:
1
Colección:
01-internacional
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Cancers (Basel)
Año:
2022
Tipo del documento:
Article
País de afiliación:
Alemania